Gilead's twice-yearly shot to prevent HIV succeeds in late-stage trial
Gilead(GILD) CNBC·2024-06-20 15:22
Gilead's experimental twice-yearly medicine to prevent HIV was 100% effective in a late-stage trial, the company said Thursday.None of the roughly 2,000 women in the trial who received Gilead's shot lenacapavir had contracted HIV by an interim analysis, prompting the independent data monitoring committee to recommend Gilead unblind the Phase 3 trial and offer the treatment to everyone in the study. Other participants had received standard daily pills.The results bring Gilead one step closer to introducing a ...